Leerink Partnrs Has Pessimistic View of ARDT Q1 Earnings

Ardent Health Partners, LLC (NYSE:ARDT) – Equities researchers at Leerink Partnrs decreased their Q1 2025 earnings per share estimates for shares of Ardent Health Partners in a report released on Monday, November 11th. Leerink Partnrs analyst W. Mayo now forecasts that the company will post earnings of $0.35 per share for the quarter, down from their previous forecast of $0.39. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Ardent Health Partners’ current full-year earnings is $1.25 per share. Leerink Partnrs also issued estimates for Ardent Health Partners’ Q2 2025 earnings at $0.58 EPS, Q3 2025 earnings at $0.49 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $1.99 EPS, FY2026 earnings at $2.27 EPS and FY2027 earnings at $2.51 EPS.

Ardent Health Partners (NYSE:ARDT) last issued its earnings results on Wednesday, August 14th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.05. The firm had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.46 billion.

A number of other analysts have also commented on ARDT. Mizuho started coverage on Ardent Health Partners in a report on Monday, August 12th. They issued an “outperform” rating and a $20.00 target price for the company. Stephens reiterated an “overweight” rating and issued a $24.00 price objective on shares of Ardent Health Partners in a report on Thursday, September 19th. Citigroup began coverage on shares of Ardent Health Partners in a research note on Monday, August 12th. They set a “buy” rating and a $21.00 target price on the stock. Loop Capital started coverage on shares of Ardent Health Partners in a research note on Monday, August 12th. They issued a “buy” rating and a $18.00 price target for the company. Finally, Morgan Stanley initiated coverage on shares of Ardent Health Partners in a report on Monday, August 12th. They set an “overweight” rating and a $27.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $21.82.

Ardent Health Partners Price Performance

Shares of ARDT opened at $16.59 on Thursday. Ardent Health Partners has a twelve month low of $14.57 and a twelve month high of $20.72. The firm’s 50 day moving average price is $18.18. The company has a quick ratio of 1.78, a current ratio of 1.91 and a debt-to-equity ratio of 0.78.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new stake in shares of Ardent Health Partners in the 3rd quarter worth $42,000. Financial Management Professionals Inc. bought a new stake in Ardent Health Partners during the third quarter valued at about $50,000. MetLife Investment Management LLC purchased a new stake in Ardent Health Partners in the third quarter worth about $135,000. Quadrature Capital Ltd bought a new position in shares of Ardent Health Partners in the third quarter worth about $229,000. Finally, Barclays PLC purchased a new position in shares of Ardent Health Partners during the 3rd quarter valued at about $385,000.

Ardent Health Partners Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.